Grünenthal GmbH and Kyowa Kirin Co., Ltd., have today announced the successful completion of a deal to form a joint venture collaboration for Kyowa Kirin International’s established medicines portfolio. The portfolio includes 13 brands across six therapeutic areas primarily focused on pain management, with the majority of revenue resulting from pain management medicines.
The joint venture will be branded as Grünenthal Meds, with Grünenthal owning a 51 percent majority share and Kyowa Kirin owning the remaining 49 percent. Grünenthal intends to fully acquire the remaining share via exercising an option at the beginning of 2026.
Commenting on the announcement, Gabriel Baertschi, Chief Executive Officer, Grünenthal, said: “Grünenthal is a global leader in pain management. With the addition of this strong portfolio, we will be able to help more patients who suffer from various forms of pain.”
Jeremy Morgan, President, Kyowa Kirin International, added: “The established medicines portfolio has a proud history of delivering life-changing value for patients. Today’s announcement now means even more patients, for many years to come, will continue to benefit from the portfolio. We are enormously grateful and proud of our colleagues who have worked tirelessly to make this Joint Venture Collaboration a reality.”
Today, Grünenthal and Kyowa Kirin have announced the successful completion of a joint venture collaboration for Kyowa Kirin International’s established medicines portfolio. The portfolio includes 13 brands across six therapeutic areas primarily focused on pain management, with the majority of revenue resulting from pain management medicines.
The joint venture will be branded as Grünenthal Meds, with Grünenthal owning a 51 percent majority share and Kyowa Kirin owning the remaining 49 percent. Grünenthal intends to fully acquire the remaining share via exercising an option at the beginning of 2026.
Gabriel Baertschi, Chief Executive Officer of Grünenthal, commented: “Grünenthal is a global leader in pain management. With the addition of this strong portfolio, we will be able to help more patients who suffer from various forms of pain.”
Jeremy Morgan, President of Kyowa Kirin International, added: “The established medicines portfolio has a proud history of delivering life-changing value for patients. Today’s announcement now means even more patients, for many years to come, will continue to benefit from the portfolio. We are enormously grateful and proud of our colleagues who have worked tirelessly to make this Joint Venture Collaboration a reality.”
Grünenthal GmbH and Kyowa Kirin Co., Ltd. have today announced the successful completion of a joint venture collaboration for Kyowa Kirin International’s established medicines portfolio. The portfolio comprises 13 brands across six therapeutic areas primarily focused on pain management, including Abstral® and PecFent® for breakthrough cancer pain, Moventig® for opioid-induced constipation, and Adcal-D3® for osteoporosis.
The joint venture will be branded as Grünenthal Meds, with Grünenthal owning a 51 percent majority share and Kyowa Kirin owning the remaining 49 percent. Grünenthal intends to fully acquire the remaining share via exercising an option at the beginning of 2026.
Commenting on the announcement, Gabriel Baertschi, Chief Executive Officer of Grünenthal, said: “Grünenthal is a global leader in pain management. With the addition of this strong portfolio, we will be able to help more patients who suffer from various forms of pain.”
Jeremy Morgan, President of Kyowa Kirin International, added: “The established medicines portfolio has a proud history of delivering life-changing value for patients. Today’s announcement now means even more patients, for many years to come, will continue to benefit from the portfolio. We are enormously grateful and proud of our colleagues who have worked tirelessly to make this Joint Venture Collaboration a reality.”
Today, Grünenthal GmbH and Kyowa Kirin Co., Ltd., have announced the successful completion of a joint venture collaboration for Kyowa Kirin International’s established medicines portfolio. The portfolio includes 13 brands across six therapeutic areas primarily focused on pain management, with the majority of revenue resulting from pain management medicines.
The joint venture will be branded as Grünenthal Meds, with Grünenthal owning a 51 percent majority share and Kyowa Kirin owning the remaining 49 percent. Grünenthal intends to fully acquire the remaining share via exercising an option at the beginning of 2026.
Gabriel Baertschi, Chief Executive Officer of Grünenthal, commented: “Grünenthal is a global leader in pain management. With the addition of this strong portfolio, we will be able to help more patients
Derick is an experienced reporter having held multiple senior roles for large publishers across Europe. Specialist subjects include small business and financial emerging markets.